Bristol-Myers Squibb Co
Stocks making the biggest moves premarket: Carvana, Bristol-Myers Squibb, Alphatec and more
Ernie Garcia, CEO, Carvana Scott Mlyn | CNBC Check out the companies making headlines before the bell Monday. Carvana — Shares of the online car seller rose more than 7% in the premarket after Piper Sandler upgraded Carvana to overweight from neutral. The firm said Carvana could double from current levels, noting that the stock is […]
Read More
Morgan Stanley calls for a 26% gain in this under-the-radar ‘safe port in the storm’
Morgan Stanley says investors looking for a hideout in this volatile market should consider putting their money in this lesser known biotechnology stock. Analyst Andrew Galler initiated coverage of Halozyme Therapeutics with an overweight rating and a $50 price target, calling the company a “safe port in a storm.” “Given the macro backdrop, we view […]
Read More
‘Big Short’ Michael Burry hints we are in the center of a current market bubble popping akin to ’08 and ’00
“The Huge Small” investor Michael Burry, ideal regarded for contacting the subprime mortgage crisis, issued a further dire prediction in a cryptic tweet, hinting that a 2000 and 2008 style market place bubble could be on its way to popping in 2022. The founder of Scion Asset Management appeared to make a checklist for indicators of […]
Read More
Stocks making the biggest moves midday: Netflix, Pinduoduo, Catalent, Bristol-Myers and more
The Netflix logo is seen on a TV remote controller, in this illustration taken January 20, 2022. Dado Ruvic | Reuters Check out the companies making headlines in midday trading. Catalent Inc. – Shares of pharmaceutical company Catalent fell 8% after earnings that disappointed Wall Street. While Catalent beat expectations for earnings, its revenue and […]
Read More
Passage of Inflation Reduction Act gives Medicare historic new powers over drug prices
A pharmacist collects medications for prescriptions at a pharmacy. Simon Dawson | Bloomberg | Getty Images Medicare is poised to renegotiate the prices of some of its most expensive drugs through a historic expansion of its power, which could reduce costs for many seniors as well as federal spending on its prescription drug plan. The […]
Read More
Investor Sarat Sethi has some stock picks to play inflation and a consumer slowdown
Investors should stick to companies that can keep generating earnings as they navigate high inflation and a consumer slowdown, according to DCLA’s Sarat Sethi. “Earnings are going to drive this market going forward,” Sethi said Monday on CNBC’s “Squawk Box.” “Not multiple expansion, not liquidity, it’s going to be where do we find earnings, and […]
Read More
Artificial intelligence drug hunters are nearing a pivotal stage in their development
Efforts to use artificial intelligence to discover drugs have been underway for about a decade but industry watchers are predicting an inflection point is nearing for investors, who have been looking for ways to determine how AI-first drug developers should be valued. AI and machine learning offer the potential to speed up the hunt for […]
Read More
Having a woman in the boardroom or C-suite drives even wider diversity, study finds
shironosov | Getty Images If you want to take a good guess at a company’s gender diversity record, you might want to first look at who its CEO or board chair is, according to the findings of a new study. Having a female CEO at the helm of a company or chairing its board tends […]
Read More
Here’s Jim Cramer’s advice to navigate this uncertain earnings season
Earnings season is entering full swing on Wall Street, and CNBC’s Jim Cramer said Monday that investors would be wise to take a wait-and-see approach toward shares of companies that are about to report quarterly numbers. “In this environment, it’s always going to be fragile on the upside and easy on the downside, because the […]
Read More
Signs point to biotech M&A heating up, Wells Fargo says. Here’s where to look
The pace of biotech deals is likely to pick up, but investors should think about smaller targets, said Wells Fargo analyst Mohit Bansal. Bansal called out both enticing valuations for small- and mid-cap biotech companies, which are now trading at an enterprise value of about one times cash, on average, and a tough regulatory environment […]
Read More